Literature DB >> 33753143

A metabolic data-driven systems pharmacology strategy for decoding and validating the mechanism of Compound Kushen Injection against HCC.

Ke-Xin Wang1, Yu-Peng Chen2, Ai-Ping Lu3, Guan-Hua Du4, Xue-Mei Qin5, Dao-Gang Guan6, Li Gao7.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Compound Kushen Injection (CKI) is a widely used TCM formula for treatment of carcinomatous pain and tumors of digestive system including hepatocellular carcinoma (HCC). However, the potential mechanisms of CKI for treatment of HCC have not been systematically and deeply studied.
AIM OF STUDY: A metabolic data-driven systems pharmacology approach was utilized to investigate the potential mechanisms of CKI for treatment of HCC.
MATERIALS AND METHODS: Based on phenotypic data generated by metabolomics and genotypic data of drug targets, a propagation model based on Dijkstra program was proposed to decode the effective network of key genotype-phenotype of CKI in treating HCC. The pivotal pathway was predicted by target propagation mode of our proposed model, and was validated in SMMC-7721 cells and diethylnitrosamine-induced rats.
RESULTS: Metabolomics results indicated that 12 differential metabolites, and 5 metabolic pathways might be involved in the anti-HCC effect of CKI. A total of 86 metabolic related genes that affected by CKI were obtained. The results calculated by propagation model showed that 6475 shortest distance chains might be involved in the anti-HCC effect of CKI. According to the results of propagation mode, EGFR was identified as the core target of CKI for the anti-HCC effect. Finally, EGFR and its related pathway EGFR-STAT3 signaling pathway were validated in vivo and in vitro.
CONCLUSION: The proposed method provides a methodological reference for explaining the underlying mechanism of TCM in treating HCC.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Compound Kushen Injection (CKI); Dijkstra model; EGFR-STAT3; Metabolomics; Systems pharmacology model

Year:  2021        PMID: 33753143     DOI: 10.1016/j.jep.2021.114043

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

Review 1.  Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges.

Authors:  Kexin Li; Kunmin Xiao; Shijie Zhu; Yong Wang; Wei Wang
Journal:  Front Pharmacol       Date:  2022-05-05       Impact factor: 5.988

2.  Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study.

Authors:  Chao Hou; Die Yang; Yusen Zhang; Yifei Li; Zhengfei He; Xiaojun Dai; Qingyun Lu; Shanshan Wang; Xiaochun Zhang; Yanqing Liu
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

3.  An advanced network pharmacology study to explore the novel molecular mechanism of Compound Kushen Injection for treating hepatocellular carcinoma by bioinformatics and experimental verification.

Authors:  Shan Lu; Ziqi Meng; Yingying Tan; Chao Wu; Zhihong Huang; Jiaqi Huang; Changgeng Fu; Antony Stalin; Siyu Guo; Xinkui Liu; Leiming You; Xiaojiaoyang Li; Jingyuan Zhang; Wei Zhou; Xiaomeng Zhang; Miaomiao Wang; Jiarui Wu
Journal:  BMC Complement Med Ther       Date:  2022-03-02

4.  Cell cycle arrest is an important mechanism of action of compound Kushen injection in the prevention of colorectal cancer.

Authors:  Jie Sun; Mei Li; Tingru Lin; Di Wang; Jingyi Chen; Yu Zhang; Qing Mu; Huiting Su; Na Wu; Aiyu Liu; Yimeng Yu; Yulan Liu; Shaojie Wang; Xin Yu; Jingzhu Guo; Weidong Yu
Journal:  Sci Rep       Date:  2022-03-14       Impact factor: 4.379

5.  Computational Metabolomics Reveals the Potential Mechanism of Matrine Mediated Metabolic Network Against Hepatocellular Carcinoma.

Authors:  Kexin Wang; Xiangmin Ye; Chuanhui Yin; Qing Ren; Yupeng Chen; Xuemei Qin; Chuanzhi Duan; Aiping Lu; Li Gao; Daogang Guan
Journal:  Front Cell Dev Biol       Date:  2022-07-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.